Rain Oncology (Rain Oncology) Debt-to-Equity : 0.01 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Rain Oncology Debt-to-Equity?

Rain Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.46 Mil. Rain Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Rain Oncology's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $67.52 Mil. Rain Oncology's debt to equity for the quarter that ended in Sep. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Rain Oncology's Debt-to-Equity or its related term are showing as below:

RAIN' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.19 Med: 0 Max: 0.01
Current: 0.01

During the past 4 years, the highest Debt-to-Equity Ratio of Rain Oncology was 0.01. The lowest was -0.19. And the median was 0.00.

RAIN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs RAIN: 0.01

Rain Oncology Debt-to-Equity Historical Data

The historical data trend for Rain Oncology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rain Oncology Debt-to-Equity Chart

Rain Oncology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

-0.19

-0.01

Rain Oncology Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial											-	-	-	-	0.01

Competitive Comparison of Rain Oncology's Debt-to-Equity

For the Biotechnology subindustry, Rain Oncology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rain Oncology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rain Oncology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Rain Oncology's Debt-to-Equity falls into.

Rain Oncology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Rain Oncology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.164	+	0.113)	/	113.036
	=	0.00

Rain Oncology's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.456	+	0)	/	67.519
	=	0.01

Rain Oncology (NAS:RAIN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Rain Oncology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Rain Oncology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rain Oncology (Rain Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rain Oncology Inc (NAS:RAIN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Jarvis Avenue, Suite 204, Newark, CA, USA, 94560

Website

https://www.rainoncology.com

Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Executives

Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Josephine Bruce	officer: Principal Fin. & Acc. Officer	8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Boxer Capital, Llc	other: See remarks.	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc.	other: See remarks	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis	other: See remarks.	PO BOX N7776, LYFORD BAHAMAS
Aaron I. Davis	director	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Erik Atkisson	officer: General Counsel and CCO	C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Avanish Vellanki	director, officer: President and CEO	8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Gorjan Hrustanovic	director	C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472